Frontlight ResearchEarly access
CompletedPhase 2
BOOSTCAMP: Boosting the endocannabinoid system before the treatment of anxiety symptoms
Key facts
- Who runs it
- Universitair Medisch Centrum Utrecht
- Where
- Netherlands1 site in 1 countryChoose a country to see its sites
- Status
- Completed
- Phase
- Phase 2
- People taking part
- 82 people enrolled
- Started
- 29 Oct 2024
- Ended
- 1 Oct 2026
- Type of study
- Interventional
- Record updated
- 29 October 2024
Who can take part
- Age
- 18 years to 64 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 12 criteriaShow less
Who can take part
- Dutch uniformed personnel, which are (former) police-officers, firefighters, ambulance paramedics, military personnel or veterans
- Age between 18-65
- Waiting for therapy for the treatment of a trauma and stressor-related and/or an anxiety disorder (as determined by the MINI PLUS psychiatric interview)
Who cannot take part
- Alcohol and/or drug dependence
- Severe co-morbidity (severe major depressive or bipolar disorder and/or psychosis)
- (a history of) epilepsy or brain damage, cardiac, renal or liver abnormalities
- (a history of) allergies to medication (adverse reactions or rash)
- Individuals taking certain medications known to have potential interactions with CBD (i.e., steroids, HMG-CoA reductase inhibitors, calcium channel blockers, antihistamines, antivirals, immune modulators, benzodiazepines, anti-arrhythmic, antibiotics, anesthetics, antipsychotics, antidepressants, anti-epileptics, beta blockers, proton pump inhibitors, NSAIDs, angiotensin II blockers, oral hypoglycemic agents, and sulfonylureas)
- Individuals that had been diagnosed with intestinal, liver, or renal diseases that would affect absorption or clearance of CBD
- Inability to adequately read or speak Dutch
- Used cannabis, synthetic cannabinoid, cannabinoid analogue, or any CBD or THC-containing product within 30 days of eligibility screening
- For women: pregnant, a wish to become pregnant, or nursing
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
to examine the effects of a 2-week administration of Cannabidiol (CBD) in alleviating anxiety symptoms before anxiety or PTSD treatments in Dutch uniformed personnel
Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- BOOSTCAMP - Boosting the endocannabinoid system before the treatment of anxiety symptoms
- Record updated
- 29 October 2024